Additionally, in patients with ALK+ NSCLC, they identified four ALK peptides (AMLDLLHVA, RPRPSQPSSL, IVRCIGVSL, VPRKNITLI) that are presented by HLA-A*02:01 and HLA-B*07:02. This evidence concerns the gene ALK and non-small cell lung carcinoma.